Jane Street’s NewAmsterdam Pharma NAMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$247K Sell
7,300
-11,200
-61% -$369K ﹤0.01% 9626
2026
Q1
$592K Sell
18,500
-59,400
-76% -$1.93M ﹤0.01% 7655
2025
Q4
$2.73M Buy
77,900
+5,500
+8% +$200K ﹤0.01% 4211
2025
Q3
$2.06M Buy
72,400
+30,700
+74% +$736K ﹤0.01% 4874
2025
Q2
$755K Sell
41,700
-4,900
-11% -$89.4K ﹤0.01% 6142
2025
Q1
$954K Sell
46,600
-6,200
-12% -$138K ﹤0.01% 5655
2024
Q4
$1.36M Buy
+52,800
New +$1.12M ﹤0.01% 4832

Other funds holding NAMS

Jane Street's NAMS Position: Q2 2026 in Review

Jane Street increased its NewAmsterdam Pharma (NAMS) stake by 187% in Q2 2026, buying an estimated $10.2M and bringing the position to 474,236 shares worth $16.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2354.

Jane Street first reported a position in NAMS in Q4 2025 and has held it in 3 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Jane Street held 474,236 shares of NewAmsterdam Pharma worth $16.1M as of Q2 2026.
  • Jane Street bought 309,035 NewAmsterdam Pharma shares in Q2 2026, an estimated $10.2M.
  • NewAmsterdam Pharma made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #2354 holding.
  • Jane Street first reported a position in NewAmsterdam Pharma in Q4 2025 and has held it in 3 quarters since.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.